<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834494</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2015-07</org_study_id>
    <nct_id>NCT02834494</nct_id>
  </id_info>
  <brief_title>Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave),</brief_title>
  <acronym>NEO-ELASTO</acronym>
  <official_title>3D Elastography (Shear Wave) : Assessment of Response to Neo-adjuvant Chemotherapy (NACT) : in Vivo Quantification, for Patients With a Locally Advanced Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for
      predicting histological response to neoadjuvant chemotherapy in patients with locally
      advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for predicting histological response to neoadjuvant chemotherapy</measure>
    <time_frame>up to 32 months</time_frame>
    <description>Measure of the tumor prior to neoadjuvant chemotherapy (T0), at T1 and T2(1stand 2nd courses of anthracycline), at mid-treatment between anthracycline and taxane chemotherapy (Tmi), at the end of chemotherapy before surgery (Tfin).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elastic properties before treatment (especially ratio between tumor and glandular breast or fat tissues close to the tumors)</measure>
    <time_frame>up to 32 months</time_frame>
    <description>Use technic Supersonic Shear Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peritumoral environmental elasticity properties</measure>
    <time_frame>up to 32 months</time_frame>
    <description>Use technic Supersonic Shear Imaging (Explorer, Supersonic Imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliable early biomarker of histological response.</measure>
    <time_frame>up to 32 months</time_frame>
    <description>Estimate under chemotherapy if early changes in tumor's elasticity can provide a reliable early biomarker of histological response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor volume changes under treatment by 3D ultrasound</measure>
    <time_frame>up to 32 months</time_frame>
    <description>Estimate tumor volume changes under treatment by 3D ultrasound and Compare with measurements obtained by other conventional imaging methods currently used for monitoring patients under neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare changes in tumor elasticity under chemotherapy to variables obtained by other imaging modalities (Breast MRI) performed in clinical routine</measure>
    <time_frame>up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare changes in tumor elasticity under neoadjuvant chemotherapy to changes in diffusion apparent coefficient by using technic Supersonic Shear Imaging (Explorer, Supersonic Imagine).</measure>
    <time_frame>up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare changes in tumor volume to histological response (Gold Standard : surgery after neoadjuvant chemotherapy according to &quot; Residual Cancer Burden &quot; score</measure>
    <time_frame>up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare predictive value (semi-quantitative et quantitative measurements) of tumor elasticity</measure>
    <time_frame>up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess vascular shape and its evolution under treatment by Ultrasensitive Doppler technic &quot;Ultra-Fast Doppler&quot;</measure>
    <time_frame>up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare tumor elasticity to conventional histological parameters</measure>
    <time_frame>6 weeks</time_frame>
    <description>For the additional biopsy (optional) under neoadjuvant chemotherapy at T2, correlation elastography to pathological parameters of peritumoral environment by analyzing conventional histological parameters.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>3D Shear Wave Elastography (SWE)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3D Shear Wave Elastography (SWE)</intervention_name>
    <description>Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.</description>
    <arm_group_label>3D Shear Wave Elastography (SWE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.</description>
    <arm_group_label>3D Shear Wave Elastography (SWE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infiltrating Breast Cancer untreated and/or locally advanced (stages I (T1c), IIa IIb,
             IIIa, IIIb, IIIc of UICC classification), whatever histological type.

          -  Neo-adjuvant chemotherapy decided.(Anthracyclines, taxanes and, for tumors
             overexpressing human epidermal growth factor receptor 2 (HER2) protein, targeted
             recombinant humanized monoclonal antibodies)

          -  Index tumor whose dimensions are between 10 to 50 mm. Multifocality, and/or
             multicentricity and/or bilaterality accepted (maximum 2 tumors by breast et tumors
             well differentiated from each other).

          -  Patients aged at least 18 years old at diagnosis

          -  Full results conventional breast exams available and no reason to achieve MRI breast
             exam

          -  Patient explanation given and consent information signed

        Exclusion Criteria:

          -  Pregnant or during lactation

          -  Personal history of ipsilateral breast cancer (ipsilateral recurrence or second cancer
             in the same breast).

          -  Patient carrier of cosmetic breast implants

          -  Person deprived of liberty or under guardianship

          -  Contraindication for receiving neo-adjuvant chemotherapy for any medical reason

          -  Inability to submit to medical monitoring of the trial for reasons of geography,
             social or psychological.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Delphine SEBBAG-SFEZ, MD</last_name>
    <phone>33+(1) 56 24 55 89</phone>
    <email>delphine.sebbagsfez@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Curie Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Delphine SEBBAG-SFEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

